18-year veteran Saharsh will position the CDMO as a premier global API process development and commercial manufacturing specialist
The milestone moves the company closer to its previously announced $120 million US expansion, with groundbreaking slated for late 2026
This follows a $6 million expansion in Rosenberg in 2025 and signals a major push to boost commercial capacity, expand R&D capabilities, and meet rising demand for US-based drug product manufacturing
The Clear Lake facility marks Clariant’s first U.S. site dedicated to PEG excipient production
The facility supports drug discovery, biomolecular research, and the development of next-generation diagnostics
The facility features 2,176 high-performance GPUs across the US and Europe
These upgrades will enable advanced development and flexible manufacturing, supporting complex therapeutics and meeting global demand for advanced pharmaceutical solutions
The trial will enroll up to 42 patients in Finland across four cohorts
The approval means US laboratories can now run both respiratory and gastrointestinal panels on the high-throughput QIAstat-Dx Rise
The facility will manufacture the critical antibiotic intermediate Amino Cephalosporanic Acid (ACA), a key component in the production of cephalosporin antibiotics
Subscribe To Our Newsletter & Stay Updated
